Curasight is pioneering first-in-class radioligand therapy targeting uPAR – the pan-tumor functional driver of invasion, angiogenesis, and metastasis
Curasight is a clinical-stage radiopharmaceutical company pioneering a uPAR-targeted theranostic platform that combines precision diagnostic imaging (uTRACE®) with 100% corresponding targeted radioligand therapy (uTREAT®).
By selectively targeting the biological drivers of cancer invasion, angiogenesis and metastasis, our approach enables personalized, pan-tumor treatment with the ambition to improve outcomes across aggressive solid tumors.
One target. One therapy. A pipeline-in-a-drug.
